Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis (full – 2010)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893662/
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
(full – 2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model (abst – 2011)http://www.ncbi.nlm.nih.gov/pubmed/21177293
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22492781
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
(full – 2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model (abst – 2011)http://www.ncbi.nlm.nih.gov/pubmed/21177293
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22492781